Quick Answer
Verrica Pharmaceuticals Inc. reported Cash and Equivalents of $30.15 million for fiscal year 2025.
Verrica Pharmaceuticals Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $30.15M | -34.9% |
| 2024 | $46.33M | -33.4% |
| 2023 | $69.55M | +102.9% |
| 2022 | $34.27M | +117.6% |
| 2021 | $15.75M | +47.4% |
| 2020 | $10.69M | +15.6% |
| 2019 | $9.24M | -10.0% |
| 2018 | $10.27M | +18.6% |
| 2017 | $8.66M | +1543.8% |
| 2016 | $527.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $21.10M | -8.1% | +37.0% |
| June 30, 2025 | $15.40M | -51.8% | -48.0% |
| March 31, 2025 | $29.59M | -39.5% | -36.1% |
| December 31, 2024 | $46.33M | -33.4% | +101.8% |
| September 30, 2024 | $22.96M | -72.8% | -28.1% |
| June 30, 2024 | $31.93M | -42.1% | -34.8% |
| March 31, 2024 | $48.94M | -18.4% | -29.6% |
| December 31, 2023 | $69.55M | +102.9% | -17.5% |
- Verrica Pharmaceuticals Inc. showed a decrease of -34.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2016–2025 period, Verrica Pharmaceuticals Inc.’s cash and equivalents has grown by 5620.5% (from $527.0 thousand to $30.15 million).
- The most recent figure is from Verrica Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: